Metraipolis › archive › dc_4cc9da581a7c

COVID-19 vaccine effectiveness among healthcare workers during the Omicron period in the country of Georgia, January - June 2022 — Europe PMC PMID:40397872

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40397872
DOI
10.1371/journal.pone.0311337
License (as archived)
CC0-1.0
Archived
2026-10-06T10:16:47.171Z
SHA-256 of the archived text
9802aefab2c6d0ee66ccb60745f2666d98d852fe19ffaa9a8de6fdf675097777
Stable URL of this page
https://metraipolis.com/documento/dc_4cc9da581a7c

How to cite

COVID-19 vaccine effectiveness among healthcare workers during the Omicron period in the country of Georgia, January - June 2022 — Europe PMC PMID:40397872 — Europe PMC (en), https://europepmc.org/article/MED/40397872 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_4cc9da581a7c (Metraipolis archive dc_4cc9da581a7c, sha256 9802aefab2c6d0ee66ccb60745f2666d98d852fe19ffaa9a8de6fdf675097777)
BibTeX
@misc{dc4cc9da581a7c,
  title = {COVID-19 vaccine effectiveness among healthcare workers during the Omicron period in the country of Georgia, January - June 2022 — Europe PMC PMID:40397872},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40397872},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_4cc9da581a7c; sha256 9802aefab2c6d0ee66ccb60745f2666d98d852fe19ffaa9a8de6fdf675097777},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40397872. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Introduction: Understanding COVID-19 vaccine effectiveness (VE) in healthcare workers (HCWs) is critical to inform vaccination policies. We measured COVID-19 VE against laboratory-confirmed symptomatic infection in HCWs in the country of Georgia from January - June 2022, during a period of Omicron circulation. Methods: We conducted a cohort study of HCWs in six hospitals in Georgia. HCWs were enrolled in early 2021. Participants completed weekly symptom questionnaires. Symptomatic HCWs were tested by RT-PCR and/or rapid antigen test (RAT). Participants were also routinely tested, at varying frequencies during the study period, for SARS-CoV-2 by RT-PCR or RAT, regardless of symptoms. Serology was collected quarterly throughout the study and tested by electrochemiluminescence immunoassay for SARS-CoV-2 antibodies. We estimated absolute and relative VE of a first booster dose compared to a primary vaccine series as (1-hazard ratio)*100 using Cox proportional hazards models. Results: Among 1253 HCWs, 141 (11%) received a primary vaccine series (PVS) and a first booster, 855 (68%) received PVS only, and 248 (20%) were unvaccinated. Most boosters were BNT162b2 (Comirnaty original monovalent) vaccine (90%) and BBIBP-CorV vaccine (Sinopharm) (9%). Most PVS were BNT162b2 vaccine (68%) and BBIBP-CorV vaccine (24%). Absolute VE for a first booster was 40% (95% Confidence Interval (CI) -56-77) at 7-29 days following vaccination, -9% (95% CI -104-42) at 30-59 days following vaccination, and -46% (95% CI -156-17) at ≥ 60 days following vaccination. Relative VE of first booster dose compared to PVS was 58% (95% CI 1-82) at 7-29 days following vaccination, 21% (95% CI -33-54) at 30-59 days following vaccination, and -9% (95% CI -82-34) at ≥ 60 days following vaccination. Conclusion: In Georgia, first booster dose VE against symptomatic SARS-CoV-2 infection among HCWs was moderately effective but waned very quickly during Omicron. Increased efforts to vaccinate priority groups in Georgia, such as healthcare workers, prior to periods of anticipated high COVID-19 incidence are essential.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-05-21).
Identificativi: PMID 40397872 · PMCID PMC12094764 · DOI 10.1371/journal.pone.0311337.
Descrittori MeSH principali: Health Personnel; COVID-19; COVID-19 Vaccines; Vaccine Efficacy.
Pagina: https://europepmc.org/article/MED/40397872 — https://doi.org/10.1371/journal.pone.0311337. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T09:45:27.607Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.